Trial Profile

Phase II proof-of-concept trial of SUVN 502 in patients with cognitive dysfunction.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 May 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Masupirdine (Primary)
Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders; Parkinson's disease; Schizophrenia
Focus Therapeutic Use
Sponsors Suven Life Sciences

Most Recent Events

19 May 2011 Planned initiation date changed from 1 Sep 2009 to 1 Dec 2011.
03 Aug 2009 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com